ENSC stock price at $0.72, Q1 earnings beat, technicals & forecast. Is ENSC stock a buy for Ensysce Biosciences? Insights on clinical trials & risks.
Introduction
Ensysce Biosciences develops abuse-deterrent opioids like PF614 for pain management. ENSC stock eyes clinical progress amid biotech funding crunch. Small-caps face volatility from rates and trial risks in tough market.
Q1 narrower loss boosts interest.
Latest Stock Price & Trend
ENSC price $0.72 Feb 27, market cap $1.43M, ranged $0.53-$0.74 (+35.2% from low). One-day down 0.88% to $2.24 in older data, recent low $1.62 Apr 2025.
Week +6.16%, month +8.74%; year -50.22% decline. Trends bearish yearly despite bounces, 52-week high 86,364 (split-adjusted?), low $1.62.
Bearish overall signals high risk for speculative plays.
Technical Analysis
Support $1.62 all-time low, $0.53 recent floor key. Resistance unclear, watch $0.74 high.
RSI 18.03 oversold (buy cue below 30). MACD -0.172 sell short-term.
Stochastic 10.93 oversold; CCI -151 confirms weakness. Volume avg 686k; oversold hints rebound potential.
Analyst Ratings & Price Targets
Average target $47.66 (high $78.75, low $18.63), massive upside from $0.72. Limited coverage; optimistic on trials.
Forecasts $382+ short-term speculative. Bullish long but thin data for caution.
Insider Activity
Routine Form 4 trades reported, no major recent buys/sells highlighted. Track record mixed profitability.
Stable trends imply neutral stance amid development.
Valuation Analysis
P/E -0.06 (losses EPS -3.80 TTM), P/S 6.83 vs. industry 1.77 (285% premium). Revenue FY $5.21M +133.6% YoY, net -$8M (-153% margin).
OCF -$7.5M burn; runway Q3 2025. Vs. biotech peers, overvalued on growth hype. Appears overvalued.
Recent Earnings & Catalysts
Q1 revenue $1.32M grant beat baseline, EPS -$1.39 beat -$3.02 est., narrower loss. PF614 Phase 3 mid-2025 start, MPAR readouts.
Patents, funding catalysts. Beat drove sentiment lift.
Bullish Case
133% revenue jump from grants. Phase 3 de-risks NDA 2026.
Abuse-deterrent edge taps OUD market. Non-dilutive funding aids runway.
Bearish Case
Persistent losses, cash burn to Q3. Trial failures common.
Competition in opioids; dilution risks high. Regulatory hurdles loom.
Market Sentiment & Investor Psychology
Short interest 240k shares (down 36%), 0.7-1.0 days low pressure. Limited options; institutions light.
Retail speculative; oversold optimistic bounce bias.
Short-Term Outlook
Oversold RSI favors snapback; MACD lag risks stall.
Medium to Long-Term Outlook
Platform de-risk via trials strong if hits. Finances tight; watch/accumulate on milestones.
FAQ
Is ENSC stock a buy right now? Speculative, oversold but high risk.
What is the price target for ENSC stock? Avg $47.66, optimistic forecasts higher.
What are major risks for ENSC stock? Trial fails, dilution, losses.
ENSC earnings outlook? Grants drive, watch Phase 3.
ENSC forecast long-term? NDA potential if trials succeed.
Suggestions
- Compare with Opendoor
- See our opioid sector forecast
- Read our small-cap biotech breakdown
Final Balanced Conclusion
Watchlist ENSC stock; catalysts promising but biotech risks prevail.
Disclaimer: This article is for informational purposes only and not financial advice.